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Liam D Turner1* and John D Harrison1,2Abstract
Background: To report a case of bilateral optic disc oedema and associated optic neuropathy in the setting of
FOLFOX chemotherapy.
Case presentation: A case of a 57-year-old male being treated with FOLFOX chemotherapy for stage 3B colorectal
cancer, who developed bilateral optic disc oedema and associated left sided optic neuropathy is described. The
patient presented following cycles 7, 8 and 9 of chemotherapy with a history of bilateral simultaneous intermittent
inferior altitudinal field defects. These episodes progressed to bilateral optic nerve oedema and a subsequent left
sided optic neuropathy. The patient’s symptoms and oedema regressed with discontinuation of chemotherapy.
Conclusion: This is the first report suggesting a vasospastic role of 5-fluoruracil in 5-FU associated optic
neuropathy. It highlights that 5-FU may have the potential to cause arterial vasospasm outside the cardiac
vasculature, resulting in end-organ optic nerve ischaemia.
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The following case report highlights the presence of bilat-
eral optic disc oedema with associated optic neuropathy
whilst undergoing FOLFOX chemotherapy. FOLFOX
chemotherapy consists of oxaliplatin, fluorouracil and leu-
covorin and has been used for the treatment of stage three
colorectal cancer since the release of early data from the
phase III MOSAIC trial in 2003 [1]. 5-Fluorouracil (5-FU)
is an antimetabolite, which inhibits the action of thy-
midylate synthase and ultimately interferes with DNA rep-
lication [1]. 5-FU has been shown to have significant
arterial vasospastic effects, which involves predominantly
the coronary arteries, resulting in ischaemia and subse-
quent infarction of the myocardium, arrhythmias and sud-
den cardiac death [2-4]. Optic neuropathy has been
documented previously when patients have been undergo-
ing 5-FU treatment, with four identified cases of optic disc
oedema and associated optic neuropathy in the setting of
continuous 5-FU infusion [5-8]. Furthermore, the National* Correspondence: lturner22@hotmail.com
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distribution, and reproduction in any mediumRegistry lists optic neuropathy as “possibly linked” to 5-
FU treatment, highlighting several cases in the academic
literature and within the registry [9]. The mechanism
for optic neuropathy has not been documented, with
some authors only postulating that 5-FU has a toxic ef-
fect on the optic nerve, which potentially may occur as
a result of dihydropyrimidine dehydrogenase deficiency
(DPD), which is the rate-limiting step in the metabolism
of 5-FU [5]. Following is a case study where the patient
developed optic disc oedema and associated optic neur-
opathy whilst undergoing 5-FU treatment, which further
provides evidence for a possible association between 5-FU
and optic neuropathy, providing the opportunity to dis-
cuss potential mechanisms for the associated toxicity.
Case presentation
A 57-year-old male with stage 3B colorectal cancer was re-
ferred by Medical Oncology to the Royal Brisbane Hospital
Ophthalmology department, with simultaneous transient
bilateral inferior altitudinal defects that would last up to
10 seconds in duration. These defects had commenced ap-
proximately four weeks earlier. The patient had no athero-
sclerotic risk factors (e.g. smoking, hypercholesterolaemia,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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hypotension, or obstructive sleep apnoea. On initial pres-
entation to the Ophthalmology department, the patient
had just completed cycle 8 of an intended 12 cycles of
FOLFOX adjuvant chemotherapy with curative intent. The
patient’s dosing schedule was oxaliplatin 165 mg (Day 1),
fluouracil 780 mg bolus dose (Day 1) with a subsequent
infusion of 1170 mg over 48 hours, and leucovorin 390 mg
(Day 1 + 2). The patient’s symptoms had occurred during
cycle 7 within the continuous infusion period, and for
a few days following the completion of the infusion.
On initial examination the patient’s visual acuity was 6/5
bilaterally. Ophthalmic examination, computerized perim-
etry and OCT retinal nerve fiber layers were unremarkable,
with no evidence of a disc at risk at this time. The bilateral
simultaneous inferior altitudinal field defects subsequently
recurred with cycles 8 and 9 of chemotherapy during the
continuous infusion and for a few days following the com-
pletion of the continuous infusion, but had not occurred in
the periods between cycles.
The patient represented two weeks later, upon comple-
tion of cycle 9 of chemotherapy, with a persistent complete
left inferior altitudinal field defect. Ophthalmic examin-
ation at this time revealed visual acuities of right 6/5-1, left
6/7.5 with a left relative afferent pupillary defect. Dilated
fundal examination revealed diffuse left sided optic disc
swelling and swelling of the superior quadrant of the right
disc (Figure 1: OCT RNFL Optic Discs). The patient subse-
quently went on to have formalized fields, which confirmed
the left inferior altitudinal defect and no obvious field defectFigure 1 (OCT RNFL Optic Discs).on the right (Figure 2: CP 24-2). At this stage, the patient’s
chemotherapy was ceased after careful discussion with the
medical oncology team, who in their expert opinion felt
that the threat of further visual loss was greater than the
potential benefit to be gained from further chemotherapy
in reducing recurrence of the disease.
Investigations were subsequently undertaken to rule out
secondary causes of the optic disc oedema (i.e. toxic, infil-
trative). The patient underwent blood examination (e.g.Figure 2 (CP 24-2).
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rotid ultrasound, holter monitor, MRI brain and orbits
and lumbar puncture. All investigations were inconclusive.
The patient was prescribed low dose aspirin 100 mg/day
and brimonidine tartate 2 times/day. Over the course of
approximately three months the patient’s symptoms did
not progress without the chemotherapy treatment and the
patient ceased to experience any further episodes of infer-
ior altitudinal field defects on the right side (the left side
now had a persistent defect). Serial ophthalmic examin-
ation revealed a stable visual acuity with resolution of
optic disc oedema and the gradual appearance of a pale
superior left optic nerve. Repeat fields showed a stable left
inferior altitudinal defect with no progression.
Conclusions
We propose that the episodes of bilateral simultaneous
altitudinal field defects and resultant bilateral optic disc
oedema with associated left optic neuropathy may be the
result of arterial vasospasm induced by 5-FU in the short
posterior ciliary arteries. 5-FU has been proven to initi-
ate arterial vasospasm, with both animal and human
studies that have demonstrated a dose response relation-
ship that abates with cessation of drug administration
[4,10]. Imaging studies have demonstrated that this vaso-
spasm is not specific to the coronary vasculature and
has been shown to be present within peripheral arteries.
Ultrasound evidence exists that demonstrates the occur-
rence of arterial vasospasm in the brachial arteries
following administration of 5-FU [11,12]. Furthermore,
5-FU has been shown in vitro to induce vasoconstriction
of vascular smooth muscle cells via activation of protein
C, which resolves with administration of protein kinase
inhibitors [4]. This highlights a biological plausibility to
our case. Moreover, the episodes of inferior altitudinal
field defects occurred in conjunction with the 5-FU infu-
sion, reflecting a close temporal relationship between drug
delivery and the development of symptoms that also
disappeared with cessation of the infusion. These symp-
toms of altitudinal field defects recurred with subsequent
cycles of reinfusion ultimately resulting in sufficient is-
chaemia to produce infarction in the form of a non-
arteritic anterior ischaemic optic neuropathy (NAION).
Upon cessation of the chemotherapy the symptoms of
intermittent altitudinal field defects (in the right eye) set-
tled and there was no progression of the ischaemic optic
neuropathy (in the left eye).
We believe that given the absence of: (1) atherosclerotic
risk factors; (2) a holter monitor showing sinus rhythm;
and (3) duplex carotid ultrasound revealing no evidence of
atherosclerotic disease, that an embolic source is unlikely.
In addition, a vasculitic cause (i.e. Giant Cell Arteritis) is
also less plausible because of a normal ESR, CRP, no his-
tory consistent with temporal arteritis, and failure toprogress despite the absence of corticosteroid treatment.
It is also considered highly improbable that individual em-
boli could be disseminated to both short posterior ciliary
arteries on the right and left eye, at exactly the same time
on multiple occasions over a period of three cycles of
chemotherapy. It is not possible to prove from a single
case that 5-FU causes short posterior ciliary artery vaso-
spasm and ultimately NAION. However, given the bio-
logical plausibility of the mechanism and the close
temporal association, we are of the opinion this should at
least be considered. Delval and Klastersky [5] discount an
ischaemic or vascular cause to 5-FU’s mechanism of optic
neuropathy, based on the absence of an altitudinal field
defect, flame-shaped haemorrhages of the disc, history of
diabetes or hypertension, or evidence for cardioembolic
disease in their patient. Given the absence of these risk
factors (i.e. atherosclerotic, cardioembolic), the vasospastic
properties of 5-FU should be considered as the primary
mechanism for the apparent vascular related visual field
defects experienced by our patient. Furthermore, whilst
oxaliplatin is known to cause peripheral neuropathy, and
reports are present in previous literature for its potential
association with optic neuropathy [13,14], the vascular na-
ture of our patients visual obscurations are not consistent
with a primary axonal mechanism as postulated for with
oxaliplatin. Finally, leucovorin is given to potentiate the ef-
fects of 5-FU in FOLFOX chemotherapy.
5-FU has been reported as a possible cause of optic
neuropathy in the past [5-8]. It is proposed that the transi-
ent visual disturbance experienced with 5-FU infusion
treatment is in fact a result of short-posterior ciliary artery
vasospasm, which further results in transient episodes of
ischaemia to the optic nerve. These patients may never
come to the attention of ophthalmologists as the distur-
bances are generally thought of as transient, with no long
lasting effects. Our case may represent an individual who
experienced these transient visual disturbances and whose
arterial vasospasm may have been more severe than usu-
ally encountered to result in permanent ischaemia and
necrotic tissue damage to the optic nerve head. We believe
that all patients undertaking FOLFOX chemotherapy who
experience visual disturbances should be examined by an
ophthalmologist to determine the exact nature of these
disturbances and to further investigate and interpret evi-
dence to identify a potential cause.
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